Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Oracle, Sight Sciences And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Published 12/09/2023, 10:40
Updated 12/09/2023, 12:10
© Reuters.  Oracle, Sight Sciences And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Benzinga - by Lisa Levin, Benzinga Editor.

U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording gains in today’s pre-market trading session.

  • Acelyrin, Inc. (NASDAQ: SLRN) shares tumbled 58.5% to $11.58 in pre-market trading as the company said primary endpoint of HiSCR75 at week 16 did not meet statistical significance in non-responder imputation primary analysis.
  • Sight Sciences, Inc. (NASDAQ: SGHT) shares fell 29.3% to $4.60 in pre-market trading after the company issued third-quarter total revenue guidance below estimates and cut FY23 revenue guidance.
  • Oracle Corporation (NYSE: ORCL) shares dipped 9.3% to $114.90 in pre-market trading. Oracle reported upbeat earnings for its first quarter, while sales fell short of expectations.
  • Canopy Growth Corporation (NASDAQ: CGC) shares declined 9.5% to $1.53 in pre-market trading. Canopy Growth shares jumped 81% on Monday following the company's presentation at the Morgan Stanley 21st Annual Global Healthcare Conference 2023.
  • CS Disco, Inc. (NYSE: LAW) shares fell 8.2% to $8.70 in pre-market trading as the company said co-founder Kiwi Camara has decided to step down from his roles as CEO and member of board. The company named Scott Hill as interim CEO.
  • AerCap Holdings N.V. (NYSE: AER) shares fell 4.5% to $59.00 in pre-market trading. AerCap priced its secondary offering of 40.68 million ordinary shares by GE Capital US Holdings at $59 per share.
  • POSCO Holdings Inc. (NYSE: PKX) shares fell 4.1% to $103.80 in pre-market trading.
  • Tango Therapeutics, Inc. (NASDAQ: TNGX) shares declined 3.5% to $7.96 in pre-market trading after jumping 17% on Monday. The FDA recently cleared Tango Therapeutics' investigational new drug application for TNG348 for BRCA 1/2 mutant and other HRD+ (Homologous Recombination Deficient) cancers.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Don’t forget to check out our premarket coverage here

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.